DK3387019T3 - Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder - Google Patents

Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3387019T3
DK3387019T3 DK16873899.5T DK16873899T DK3387019T3 DK 3387019 T3 DK3387019 T3 DK 3387019T3 DK 16873899 T DK16873899 T DK 16873899T DK 3387019 T3 DK3387019 T3 DK 3387019T3
Authority
DK
Denmark
Prior art keywords
relaxin
methods
proteins
immunoglobulin infusion
immunoglobulin
Prior art date
Application number
DK16873899.5T
Other languages
English (en)
Inventor
Ying Wang
Guangsen Fu
Peter G Schultz
Feng Wang
Yan Liu
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK3387019T3 publication Critical patent/DK3387019T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C07K16/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16873899.5T 2015-12-09 2016-12-09 Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder DK3387019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265344P 2015-12-09 2015-12-09
PCT/US2016/065779 WO2017100540A2 (en) 2015-12-09 2016-12-09 Relaxin immunoglobulin fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
DK3387019T3 true DK3387019T3 (da) 2022-01-10

Family

ID=59013561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16873899.5T DK3387019T3 (da) 2015-12-09 2016-12-09 Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder

Country Status (6)

Country Link
US (2) US11161891B2 (da)
EP (2) EP3387019B1 (da)
DK (1) DK3387019T3 (da)
ES (1) ES2903257T3 (da)
PT (1) PT3387019T (da)
WO (1) WO2017100540A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
MA46436A (fr) * 2016-10-07 2019-08-14 Beth Israel Deaconess Medical Ct Inc Compositions comprenant de la relaxine et leurs méthodes d'utilisation
KR102584675B1 (ko) * 2018-05-23 2023-10-05 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021163346A2 (en) * 2020-02-12 2021-08-19 The Scripps Research Institute Long-acting gm-csf and methods of use
CA3186143A1 (en) * 2020-06-17 2021-12-23 Medimmune Limited Heterodimeric relaxin fusions and uses thereof
CA3237801A1 (en) * 2021-11-11 2023-05-19 John Diener Relaxin-2 fusion protein analogs and methods of using same
IL321288A (en) * 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers
WO2024238955A2 (en) * 2023-05-18 2024-11-21 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
ATE474854T1 (de) 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
CA2397200C (en) 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
AU2012211451A1 (en) 2000-03-01 2012-08-30 Applied Molecular Evolution, Inc. High potency recombinant antibodies and method for producing them
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6740747B2 (en) 2001-04-20 2004-05-25 Azad Kaushik Bovine VDJ cassette, BF1H1, suitable for antigenization
US20080260731A1 (en) 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20050186526A1 (en) 2002-11-01 2005-08-25 Bas Medical, Inc. Methods and systems for enabling and stabilizing tooth movement
US6984128B2 (en) 2002-11-01 2006-01-10 Bas Medical, Inc. Methods for enabling and stabilizing tooth movement
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
JP4836942B2 (ja) 2004-04-30 2011-12-14 コーセラ， インコーポレイテッド リラキシンの調節による胎仔の発育の制御のための方法および組成物
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20070293485A1 (en) * 2006-06-03 2007-12-20 John Lim Drug administration methods
EP2288367B1 (en) 2008-05-16 2015-10-07 Corthera, Inc. H2 relaxin for use in the treatment of premature cervical dilation
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
CA2724308C (en) 2008-05-16 2016-08-16 Corthera, Inc. Method of promoting wound healing
CA2724535A1 (en) 2008-05-16 2009-11-19 Elaine Unemori Use of relaxin to treat chronic heart failure
DK2396036T3 (da) 2009-02-13 2017-10-16 Immunomedics Inc Immunkonjugater med en intracellulært spaltbar forbindelse
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
CN102883742B (zh) 2010-03-10 2014-09-24 佛罗里达大学研究基金会有限公司 用松弛素调节水孔蛋白
US20110243942A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Relaxin-fusion proteins with extended in vivo half-lives
EP2717924A4 (en) 2011-06-10 2015-04-22 Harvard College MODULATION OF BETA CELL PROLIFERATION IN THE PANCREATIC GLAND
WO2012169822A2 (ko) 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
CN103930440A (zh) * 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
MX2014000316A (es) 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
US20170327577A1 (en) 2014-06-06 2017-11-16 The California Institute For Biomedical Research Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2018013483A1 (en) * 2016-07-11 2018-01-18 The California Institute For Biomedical Research Kv1.3 channel blocking peptides and uses thereof

Also Published As

Publication number Publication date
US20190263882A1 (en) 2019-08-29
EP3387019A2 (en) 2018-10-17
EP4011919A2 (en) 2022-06-15
PT3387019T (pt) 2022-01-14
WO2017100540A2 (en) 2017-06-15
EP3387019B1 (en) 2021-10-20
US20220048969A1 (en) 2022-02-17
EP3387019A4 (en) 2019-04-17
US12275771B2 (en) 2025-04-15
WO2017100540A3 (en) 2017-07-20
US11161891B2 (en) 2021-11-02
ES2903257T3 (es) 2022-03-31
EP4011919A3 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL282372A (en) Haploid induction compositions and methods for use therefor
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
IL255269A (en) Compositions of obeticholic acid and methods of use
IL282048A (en) Oxysterols and methods of use thereof
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
IL251970B (en) Anti-cd79b antibodies and methods of use
IL251972B (en) Analyzing and utilizing landscapes
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
IL246383A0 (en) Polyoxometalate and heteropolyoxometalate compositions and methods for their use
DK3828194T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3514151T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka